News
Researchers based in Switzerland can once again apply for ERC grants
As negotiations between the EU and Switzerland have been officially launched today, researchers based in Switzerland can now once again apply for ERC grants. This follows the adoption of the Swiss and EU negotiating mandates on 8 and 12 March 2024 respectively. The two mandates authorise Switzerland and the Commission to negotiate the…
Read MoreAlithea Genomics closes CHF 2.8 Million in seed financing extension
This milestone marks a significant step forward in the company’s journey to revolutionise large-scale RNA sequencing and transcriptomics. Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing. The round was led by…
Read MorePeriVision announces FDA registration for its medical software VisionOne™
PeriVision, proudly announces its recent FDA registration for its first medical software product VisionOne. This significant milestone marks a pivotal moment in PeriVision’s mission to enhance patient care and revolutionise the field of ophthalmology. With VisionOne, ophthalmologists and optometrists can easily configure eye tests on portable VR headsets and subsequently analyse the results…
Read MorePristem affordable radiology thrives in South Africa
A few months ago, Pristem’s South African subsidiary opened its first state-of-the-art, affordable radiology center in the township of Alexandra. The Swiss medtech is due to open a second one in Soweto this month, and has big plans for the future. Through its Open Diagnostics brand, Pristem is on a mission to provide…
Read MoreUS FDA grants Orphan Drug Designation for iOnctura’s Autotaxin cancer therapy
iOnctura’s autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer gets Orphan Drug Designation (ODD) by the US FDA. IOnctura is a pioneering clinical-stage biotechnology company developing transformative cancer therapies. After assessing its novel chemical and biological properties including an attractive non-clinical safety and efficacy profile, the US Food and Drug Administration (FDA) has…
Read MoreDebiopharm launches expansion of WEE1 inhibitor
Debiopharm aims to further characterise the safety, tolerability, and preliminary anti-tumour activity of its potent WEE1 inhibitor Debio 0123 as monotherapy in three different expansion cohorts. Debiopharm announced the first patient dosed in the expansion of its open-label, non-randomised, multicenter Phase 1 study evaluating Debio 0123, an oral, potent, highly selective and…
Read MoreCollaboration between ABCDx and Andalusian Hospitals
ABCDx is collaborating with Andalusian hospitals to improve stroke triage inside ambulances. Thanks to a public-private grant from the Junta de Andalucía (PIP-0009-2021), the Hospital Universitario Virgen Macarena/IBIS is leading a study to evaluate the potential use of a rapid Point-of-Care device for the direct transfer of stroke patients with a large vessel…
Read MoreSix women-centred initiatives you should know about
From successful entrepreneurs to academics and industry leaders, the Swiss Health Valley is full of inspirational women working in life sciences. As we celebrate Women International’s Day, we’re happy to highlight some of the great initiatives pushing to close the gender gap in life sciences that everybody should keep an eye on. …
Read MoreA multidisciplinary HUG team launches a new study of innovative radioligand therapy (RLT)
A new radioligand to treat glioblastoma and digestive tumors evaluated as a world first at the Geneva University Hospitals (HUG). RLT is a nuclear medicine-based approach that destroys malignant tumors through targeted irradiation. Its specificity lies in the use of a radioactive element embedded in a chemical compound designed to bind specifically to…
Read MoreTerapet receives EUR 1.68 Million Eurostars grant
Terapet announced the receipt of a non-dilutive grant totalling approximately EUR 1.68 Million from the European Commission through the Eurostars Program. Terapet SA, is a Geneva-based CERN spin-off supported by FONGIT, developing an innovative platform technology for imaging in nuclear medicine. The received grant is supported by Innosuisse – the Swiss Innovation Agency,…
Read More